
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
Experience flexibility with TaqMan assays, offering over 2.8 million predesigned options to meet your specific needs.







